10x Genomics is trading at $54.80 (+5.32%) as it extends its August 7, 2026 post-earnings rally after raising full-year 2026 guidance.
- Second-quarter revenue was $151.0 million, with full-year 2026 guidance raised to $610 million–$630 million.
- Management highlighted strong early demand for the Atera spatial platform, with shipments expected to accelerate in the fourth quarter.
- The broader market is mixed, so company-specific earnings momentum appears to be the primary catalyst.